drugset / Trial / NCT07090525
Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma
Timeline
- Start
- 2025-07-01
- Primary completion
- 2026-12-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Other |
| Comparator | Cisplatin | Other / unclassified | 40 mg/m2 | Other |
Indications
No indication recorded.